News Sentiment

NVCR sentiment intelligence

Novocure Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 16.30 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-5.2% over one week, -8.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

JPMorgan Initiates Coverage on Novocure (NVCR) with Neutral Outl

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -5.2% Price reacting lower
Trend fit Trend active -8.3% over four weeks
Fair value -4.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 44
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 12
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
Stock Titan 10
TradingView 5
GuruFocus 4
Simply Wall Street 3
Seeking Alpha 3
The Motley Fool 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 25
Analyst action 4
Regulatory and legal 4
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
GuruFocus Direct company coverage

NVCR Reinstated by JP Morgan -- Rating Remains Neutral

JP Morgan has reinstated coverage on NovoCure (NVCR) with a price target of $17.00 and a Neutral rating. While GuruFocus's GF Value™ suggests NVCR is modestly undervalued at $18.71, insider activity shows $0.9 million in shares sold recently, indicating a cautious outlook among i

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 12:10
Source
GuruFocus
Investing.com Direct company coverage

JPMorgan resumes NovoCure stock coverage with neutral rating

JPMorgan has reinstated coverage of NovoCure Ltd. (NASDAQ:NVCR) with a Neutral rating and a $17.00 price target for December 2027. The firm anticipates profitability by 2028, driven by new launches in pancreatic cancer and brain metastases. The company's valuation reflects its ma

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 08:10
Source
Investing.com
Simply Wall Street Direct company coverage

Does NovoCure’s Shift Into Russell Value Indexes Recast NVCR’s Core Investment Narrative?

NovoCure Limited (NasdaqGS: NVCR) was recently included in several Russell value indexes in late June 2026, categorizing it as a value-oriented medical technology company. While this inclusion offers increased visibility, it doesn't fundamentally change the company's investment n

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:10
Source
Simply Wall Street
TradingView Direct company coverage

Price to book forward of NovoCure Ltd. – FWB:038

This article provides the "Price to book forward" value for NovoCure Ltd. (FWB:038). It indicates that the period value for this metric is 0, with no change or percentage change data available. The information is presented within a financial market data context on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 16:12
Source
TradingView
AD HOC NEWS Direct company coverage

NVCR stock. NovoCure’s business case stays in view.

This article discusses NovoCure Ltd. (NVCR), a cancer care company known for its tumor treating fields platform, including its flagship product Optune. It highlights the company's business model, particularly its focus on recurring adoption, reimbursement, and physician familiari

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 15:13
Source
AD HOC NEWS
Simply Wall Street Direct company coverage

Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation?

NovoCure (NVCR) is under scrutiny after a legal investigation following its Phase 3 TRIDENT trial results caused a significant stock drop, despite recent short-term gains. Currently, the stock is considered 34% undervalued with a fair value of $26.07 against its last close of $17

Tone
Neutral 50/100
Event
Regulatory and legal
Published
06 Jul 2026 18:40
Source
Simply Wall Street
Market source Direct company coverage

Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

Novocure announced that its Optune Pax® device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer, in conjunction with gemcitabine and nab-paclitaxel. This approval is based on results from the Phase 3 PANOVA-3 trial, which showed a

Tone
Positive 72/100
Event
Earnings
Published
04 Jul 2026 07:09
Source
Market source
Stock Titan Direct company coverage

NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase

NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 1,905 ordinary shares through the company's 2025 Employee Share Purchase Plan on June 30, 2026. The shares were purchased at a discounted price of $11.15 each, representing 85% of the closing price on Janua

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 16:39
Source
Stock Titan
Market source Direct company coverage

NovoCure's Cancer Treatment Device Option Pax Gets European Approval

NovoCure Limited has received CE mark approval for its portable medical device, Option Pax, to treat locally advanced pancreatic cancer in Europe. This treatment, used concomitantly with gemcitabine and nab-paclitaxel, had previously received FDA approval and will be launched in

Tone
Positive 66/100
Event
Regulatory and legal
Published
02 Jul 2026 10:00
Source
Market source
Market source Direct company coverage

Novocure to Report Second Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) is set to announce its financial results for the second quarter of 2026 on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure, a glo

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 06:10
Source
Market source
Stock Titan Direct company coverage

NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings

NovoCure Ltd's General Counsel, Ben Arye Barak, acquired 1,299 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) for the period of January 1, 2026, through June 30, 2026. The shares were purchased at a reported price of $11.15 each, bringing his direc

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan

NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) at $11.15 per share. This routine, compensation-related transaction, exempt under Rule 16b-3(c), increased Danziger's direct holdings to 416,742 ordinar

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan

NovoCure's CEO, Leonard Frank X, acquired 1,905 ordinary shares at $11.15 each through the company's 2025 Employee Share Purchase Plan for the first half of 2026. This transaction is exempt under Rule 16b-3(c) and increases his direct holdings to 461,425 ordinary shares. The purc

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Novocure sets July 23 call for Q2 2026 results before markets open

Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure is an oncology company s

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 11:40
Source
Stock Titan
Finviz Direct company coverage

NVCR - NovoCure Ltd Volatility & Greeks

This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and inst

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:09
Source
Finviz
Investing.com Direct company coverage

Novocure receives CE Mark for pancreatic cancer device in Europe

Novocure's Optune Pax device has received CE Mark approval in Europe for treating locally advanced pancreatic cancer when used with chemotherapy. This approval is based on Phase 3 trial results showing improved overall survival and time to pain progression for patients using Optu

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 11:39
Source
Investing.com
grafa.com Direct company coverage

Novocure wins CE Mark for Optune Pax pancreatic cancer treatment

Novocure's Optune Pax device has received CE Mark approval for treating locally advanced pancreatic cancer in Europe, following prior U.S. approval. The approval is based on Phase 3 PANOVA-3 trial results showing a 2-month median overall survival benefit and improved quality of l

Tone
Positive 72/100
Event
Earnings
Published
30 Jun 2026 11:20
Source
grafa.com
Stock Titan Direct company coverage

Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe

Novocure's wearable medical device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in Europe. This approval is based on data from the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in overall survival and de

Tone
Positive 73/100
Event
Regulatory and legal
Published
30 Jun 2026 11:10
Source
Stock Titan
Stock Titan Direct company coverage

Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach

Novocure's wearable device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in adults when used with gemcitabine and nab-paclitaxel. This approval is supported by positive Phase 3 PANOVA-3 trial data, which showed significant improvements

Tone
Positive 75/100
Event
Regulatory and legal
Published
30 Jun 2026 11:10
Source
Stock Titan
Sahm Direct company coverage

NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start

NovoCure's stock rose 8.1% after its Phase 3 TRIDENT trial revealed no significant survival benefit from starting Tumor Treating Fields (TTFields) earlier for glioblastoma patients. The results indicate that the timing of TTFields initiation, rather than the therapy's feasibility

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 15:40
Source
Sahm
TradingView Direct company coverage

NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh

This article provides an overview of NovoCure Ltd. (N2VC34) stock, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics for both annual and quarterly periods

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 07:39
Source
TradingView
Simply Wall Street Direct company coverage

NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results

NovoCure (NVCR) is considered potentially 42% undervalued despite reporting mixed topline Phase 3 TRIDENT data for glioblastoma that showed no statistically significant overall survival benefit. The stock's current price of US$15.05 is a significant discount to its estimated fair

Tone
Positive 63/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
Simply Wall Street
TradingView Direct company coverage

NVCR Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for NovoCure Limited (NVCR) stock, based on analysis from several financial experts. It details the current stock price, historical performance, and analysts' maximum and minimum price estimates for the company. Additionally, the

Tone
Neutral 50/100
Event
Guidance
Published
26 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR)

This article provides an overview of NovoCure Limited (NASDAQ: NVCR) stock, including current price, historical performance, analyst forecasts, and detailed financial data. It covers earnings, revenue, market capitalization, EBITDA, and upcoming earnings report dates. The article

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:10
Source
TradingView